Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical has raised £5 million (C$9.23 million) through a placing and subscription of 41,666,667 new common shares at 12p, with strong backing from existing shareholders and participation by several directors, some subscribing in lieu of remuneration. The funds will support completion of its Phase 3 clinical study report, GMP commercial-scale production and stability work, FDA interactions including a planned pre-NDA meeting, and general commercial and operational needs, extending its cash runway to early Q4 2026 while increasing its issued share capital to 561,218,135 shares.
Following admission of the new shares, expected on 5 May 2026, Ondine’s common shares will rank pari passu with existing stock, and directors’ subscriptions have been deemed fair and reasonable by independent board members after adviser consultation. The fundraising positions the company to advance its Steriwave programme toward regulatory submission and commercialization, potentially strengthening its competitive standing in infection-control markets and providing greater visibility for shareholders as total voting rights are updated.
Spark’s Take on OBI Stock
According to Spark, TipRanks’ AI Analyst, OBI is a Underperform.
Ondine Biomedical, Inc. receives a low overall score due to significant financial performance challenges, bearish technical indicators, and unattractive valuation metrics. The company’s strong revenue growth is overshadowed by its inability to achieve profitability and positive cash flow, while technical analysis suggests continued negative momentum.
To see Spark’s full report on OBI stock, click here.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company listed on AIM that develops medical therapies, including its Steriwave photodisinfection technology, targeting infections in markets with significant unmet need. The company is progressing late-stage clinical and regulatory work, including a Phase 3 LANTERN study and preparations for a New Drug Application in the United States.
Average Trading Volume: 269,651
Technical Sentiment Signal: Buy
Current Market Cap: £64.8M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.